Chengdu Kanghong Pharmaceuticals (688222.SH): Currently, most of the company's independently developed new drug projects are in different stages before clinical trials, with a high level of uncertainty in their development.
Zhito Financial APP News, Chengdu Lead (688222.SH) released a stock price abnormality announcement stating that new drug research and development has the characteristics of high technology, high risk, and high added value. The product has a long cycle from research and development, clinical trial approval to production, with many links, and is easily affected by uncertain factors. Currently, most of the company's self-developed new drug projects are in different stages of pre-clinical development, and the development is highly uncertain. There is significant uncertainty about whether the subsequent external transfer can be realized.
Latest